Page last updated: 2024-11-08

ginsenoside re

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
PanaxgenusAn araliaceous genus of plants that contains a number of pharmacologically active agents used as stimulants, sedatives, and tonics, especially in traditional medicine. Sometimes confused with Siberian ginseng (ELEUTHEROCOCCUS).[MeSH]AraliaceaeThe ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH]
Panax ginsengspecies[no description available]AraliaceaeThe ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH]

Cross-References

ID SourceID
PubMed CID441921
CHEMBL ID510095
CHEBI ID77148
SCHEMBL ID669738
MeSH IDM0142681

Synonyms (41)

Synonym
nsc 308877
einecs 257-814-6
2-o-(6-deoxy-alpha-l-mannopyranosyl)-(3beta,6alpha,12beta)-20-(beta-d-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl-beta-d-glucopyranoside
nsc-308877
ginsenoside re ,
52286-59-6
C08944
ginsenoside b2
chikusetsusaponin ivc
panaxoside re
ginsenoside-re
sanchinoside re
CHEMBL510095 ,
chebi:77148 ,
A829010
S3811
unii-46f3r0bl3i
46f3r0bl3i ,
bdbm50378779
ginsenoside re [inci]
ginsenoside re (constituent of american ginseng, asian ginseng, and tienchi ginseng) [dsc]
.beta.-d-glucopyranoside, (3.beta.,6.alpha.,12.beta.)-20-(.beta.-d-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-o-(6-deoxy-.alpha.-l-mannopyranosyl)-
AKOS025310861
SCHEMBL669738
CS-3838
(3beta,6alpha,12beta)-20-(beta-d-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside
(3beta,6alpha,12beta)-20-(beta-d-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-o-(alpha-l-rhamnopyranosyl)-beta-d-glucopyranoside
(20s)-ginsenoside re
AC-33946
HY-N0044
mfcd00133369
PWAOOJDMFUQOKB-WCZZMFLVSA-N
DB14815
Q27105064
b-d-glucopyranoside,(3b,6a,12b)-20-(b-d-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-o-(6-deoxy-a-l-mannopyranosyl)-
CCG-270589
EX-A6794
DTXSID801317298
ginsenoside re (constituent of american ginseng, asian ginseng, and tienchi ginseng)
beta-d-glucopyranoside, (3beta,6alpha,12beta)-20-(beta-d-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-o-(6-deoxy-alpha-l-mannopyranosyl)-
G0551

Research Excerpts

Overview

Ginsenoside Re is an active component in ginseng that confers protection against myocardial ischemia/reperfusion (I/R) injury. Ginsenoside re is an extract from Panax notoginseng, which is a well-known traditional Chinese medicine that has been used for the treatment of various diseases.

ExcerptReferenceRelevance
"Ginsenoside Re (GRe), is a main bioactive component of ginseng, shows very specific anti-apoptotic, antioxidant and anti-inflammatory activities."( Presence of ginsenoside re during in vitro maturation protects porcine oocytes from heat stress.
Duan, AY; Gao, LP; Ju, AQ; Liu, S; Ma, X; Yang, SB; Zhan, CL, 2022
)
1.82
"Ginsenoside Re is an active component in ginseng that confers protection against myocardial ischemia/reperfusion (I/R) injury. "( Ginsenoside Re attenuates myocardial ischemia/reperfusion induced ferroptosis via miR-144-3p/SLC7A11.
Gao, JQ; Li, LY; Liu, Y; Liu, ZJ; Lyu, TJ; Wang, X; Xi, X; Ye, J; Zhang, H, 2023
)
3.8
"Ginsenoside Re (Re) is a major active ingredient of ginseng having multifaceted pharmacological effects on the cardiovascular system, and is a potential treatment for restenosis."( Inhibition of the Ras/ERK1/2 pathway contributes to the protective effect of ginsenoside Re against intimal hyperplasia.
Gao, C; Hu, H; Jiang, X; Liang, F; Ma, W; Sonkoly, E; Wang, H; Zhan, H; Zhang, K; Zhao, Z, 2021
)
1.57
"Ginsenoside Re is a triol type triterpene glycoside and is abundantly present in ginseng berry. "( Anticarcinogenic effects of products of heat-processed ginsenoside Re, a major constituent of ginseng berry, on human gastric cancer cells.
Choi, KC; Eom, DW; Ham, J; Han, IH; Hwang, GS; Jang, HJ; Kang, KS; Kim, SN; Kim, YJ; Lee, D; Oh, M; Yamabe, N, 2014
)
2.09
"Ginsenoside Re (Re) is a saponin isolated from Panax ginseng, and has an adjuvant property."( Ginsenoside Re as an adjuvant to enhance the immune response to the inactivated rabies virus vaccine in mice.
Hu, S; Pei, Z; Su, X, 2014
)
2.57
"Ginsenoside Re is an active component in ginseng that has attracted much attention because of its evident therapeutic effects on the cardiovascular system. "( Proteomic analysis of ginsenoside Re attenuates hydrogen peroxide-induced oxidative stress in human umbilical vein endothelial cells.
Deng, ZY; Huang, GD; Zeng, R; Zhong, XF, 2016
)
2.19
"Ginsenoside Re is an extract from Panax notoginseng, which is a well-known traditional Chinese medicine that has been used for the treatment of various diseases for years."( Ginsenoside Re reduces Aβ production by activating PPARγ to inhibit BACE1 in N2a/APP695 cells.
Cao, G; Guo, L; Liang, Y; Qin, C; Su, P; Zhang, H; Zhang, S; Zhang, W, 2016
)
2.6
"The ginsenoside Re is an active constituent in ginseng."( [Structure and vibrational spectroscopy of ginsenoside Re: density functional theory study].
Hui, G; Shang, XH; Wang, X; Wu, FQ; Zhao, B; Zhao, DQ; Zhao, Y, 2009
)
1.1
"Ginsenoside Re (G-Re) is a major ingredient of the ginseng bud. "( Separation and purification of ginsenoside Re from ginseng bud by selective adsorption of active carbon and preparative high-performance liquid chromatography.
Kuang, P; Liang, H; Wang, G; Yuan, Q, 2012
)
2.11
"Ginsenoside Re is a protopanaxatriol-type saponin isolated from Panax ginseng berry. "( Ginsenoside Re lowers blood glucose and lipid levels via activation of AMP-activated protein kinase in HepG2 cells and high-fat diet fed mice.
Chung, SH; Jung, MS; Ko, SK; Park, YG; Quan, HY; Yuan, HD, 2012
)
3.26
"Ginsenoside Re (GRe) is a major active component of the Chinese medicinal herb ginseng, Panax ginseng . "( Development of a secondary antibody thio-functionalized microcantilever immunosensor and an ELISA for measuring ginsenoside Re content in the herb ginseng.
Li, Z; Nan, T; Tan, W; Wang, B; Wu, S; Zhang, Q; Zhao, H, 2012
)
2.03

Effects

Ginsenoside Re (G-Re) has been found to ameliorate the symptoms and pathological impairments of AD. The mechanism has not been fully elucidated.

ExcerptReferenceRelevance
"Ginsenoside Re (G-Re) has been found to ameliorate the symptoms and pathological impairments of AD."( Kidney Yang Deficiency Syndrome Exacerbates Aβ
Chen, L; Fu, Q; Jiang, X; Liu, XT; Ma, DL; Wang, XY, 2023
)
1.63
"Ginsenoside Re (Re) has pharmacological effects against Aβ-induced neurotoxicity."( Ginsenoside Re Inhibits ROS/ASK-1 Dependent Mitochondrial Apoptosis Pathway and Activation of Nrf2-Antioxidant Response in Beta-Amyloid-Challenged SH-SY5Y Cells.
Bai, X; Liu, M; Liu, Y; Qiao, J; Wang, J; Wang, S; Yu, S; Zhao, D; Zhao, W, 2019
)
2.68
"Ginsenoside Re has been reported to decrease Aβ in Alzheimer's disease animal models, but the mechanism has not been fully elucidated."( Ginsenoside Re reduces Aβ production by activating PPARγ to inhibit BACE1 in N2a/APP695 cells.
Cao, G; Guo, L; Liang, Y; Qin, C; Su, P; Zhang, H; Zhang, S; Zhang, W, 2016
)
2.6
"Ginsenoside Re has the same metabolic pathway with microorganisms, to some extent, justified the use of microbial models for mammalian metabolism studies."( [Metabolic study of ginsenoside Re in rats].
Chen, G; Guo, D; Yang, M, 2009
)
2.12

Treatment

Treatment with ginsenoside Re resulted in significant attenuations against a decrease in the activity of GPx and an increase in the Activity of superoxide dismutase (SOD) The effect may be attributable to inhibition of release of LDH and improvement of the GJIC function.

ExcerptReferenceRelevance
"Ginsenoside Re pretreatment, particularly with a dose of 20 g/L, can protect myocardial cells from hypoxia injury, and the effect may be attributable to inhibition of release of LDH and improvement of the GJIC function."( [Protective effect of ginsenoside Re on myocardial cells of neonatal SD rat subjected to hypoxia injury].
Li, XF; Luo, QZ; Shi, XH, 2011
)
2.13
"Treatment with ginsenoside Re significantly attenuated methamphetamine-induced dopaminergic degeneration in vivo by inhibiting impaired enzymatic antioxidant systems, mitochondrial oxidative stress, mitochondrial translocation of protein kinase Cδ, mitochondrial dysfunction, pro-inflammatory microglial activation, and apoptosis."( Ginsenoside Re rescues methamphetamine-induced oxidative damage, mitochondrial dysfunction, microglial activation, and dopaminergic degeneration by inhibiting the protein kinase Cδ gene.
Jang, CG; Kim, HC; Ko, SK; Nabeshima, T; Nah, SY; Nguyen, TT; Park, DH; Shin, EJ; Shin, SW; Wie, MB; Yang, BW, 2014
)
2.18
"Treatment with ginsenoside Re resulted in significant attenuations against a decrease in the activity of GPx and an increase in the activity of superoxide dismutase (SOD) in the cytosolic and mitochondrial fraction."( Ginsenoside Re protects methamphetamine-induced mitochondrial burdens and proapoptosis via genetic inhibition of protein kinase C δ in human neuroblastoma dopaminergic SH-SY5Y cell lines.
Jang, CG; Jeong, JH; Kim, HC; Ko, SK; Nah, SY; Nam, Y; Nguyen, TT; Shin, EJ; Wie, MB, 2015
)
2.2
"Pretreatment with ginsenoside Re (5 mg/kg) also decreased kaolin intake (P<0.05)."( American ginseng berry extract and ginsenoside Re attenuate cisplatin-induced kaolin intake in rats.
Aung, H; Mehendale, S; Wang, A; Wang, CZ; Xie, JT; Yin, JJ; Yuan, CS, 2005
)
0.93

Toxicity

ExcerptReferenceRelevance
"Ginsenoside Re did not induce death, adverse effects or dose-dependent changes in feed consumption, or body weight gain."( Chronic toxicity of ginsenoside Re on Sprague-Dawley rats.
Li, P; Liu, J; Lu, D; Zhao, W, 2012
)
2.15

Pharmacokinetics

LC-MS/MS method was established to analyze five ingredients. Ginsenoside Re was rapidly cleared from the body with a short half-life.

ExcerptReferenceRelevance
"Ginsenosides Rg1 and Re in plasma were determined by LC/MS/MS and the pharmacokinetic parameters were calculated."( [Pharmacokinetics of ginsenosides Rg1 and Re in Shenmai injection].
Deng, YH; Feng, Y; Liang, WX; Liu, YM; Yang, L; Zeng, X, 2005
)
0.33
" The distribution and elimination of Rg1 and Re were rapid after iv infusion of Shenmai injection in volunteers, the pharmacokinetic characteristics were fitted with the two-compartment model."( [Pharmacokinetics of ginsenosides Rg1 and Re in Shenmai injection].
Deng, YH; Feng, Y; Liang, WX; Liu, YM; Yang, L; Zeng, X, 2005
)
0.33
" Ginsenoside Re was rapidly cleared from the body with a short half-life (0."( Pharmacokinetic study of ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse using ultra performance liquid chromatography/mass spectrometric method.
Hong, DK; Jeon, HY; Jeong, HJ; Joo, KM; Lee, JH; Lee, SJ; Lee, SY; Lim, KM; Park, CW, 2010
)
1.57
" The peak concentration (C(max)) occurred at 60 min for all doses."( Pharmacokinetics and dopamine/acetylcholine releasing effects of ginsenoside Re in hippocampus and mPFC of freely moving rats.
Li, KX; Shi, J; Xue, W; Zhao, WJ, 2013
)
0.63
" The method was successfully applied to a pharmacokinetic study of Xuesaitong dispersible tablets in eight rats."( Simultaneous determination of notoginsenoside R1 and ginsenoside Re in rat plasma by ultra high performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study.
Dai, G; Jiang, Z; Ju, W; Li, C; Liu, S; Zhang, Q; Zhu, L; Zong, Y, 2016
)
0.68
"LC-MS/MS method was established to analyze five ingredients, notoginsenoside R1 (R1), ginsenoside Rg1 (Rg1), ginsenoside Rb1 (Rb1), ginsenoside Re (Re), and ginsenoside Rd (Rd), in rats' plasma to describe the pharmacokinetic parameters of PNS."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.69
"The pharmacokinetic parameters were significantly different after oral administration three formulations."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.48
" However, the pharmacokinetic characteristics of its major bioactive components under pathological conditions are unclear."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91
"This method was successfully applied to the pharmacokinetic investigation of seven major components of C-QSP and P-QSP following oral administration in CHF model rats."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91
"The pharmacokinetic parameters of bioactive components were significantly changed for better bioavailability and absorption, longer lasting time elimination, which were beneficial for enhancing therapeutic efficacy in the P-QSP group."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" A microdialysis combined with UPLC-MS/MS method was first established to compare the pharmacokinetics of seven major bioactive components in CHF model rats after oral administration of C-QSP and P-QSP."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" Poor systemic bioavailability might be responsible for the absence of a therapeutic effect."( Ginseng and ginsenoside Re do not improve β-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes.
Holloszy, JO; Klein, S; Okunade, A; Patterson, BW; Polonsky, KS; Reeds, DN, 2011
)
0.75
" The application is restricted by low bioavailability partly due to Panax notoginseng saponins (PNS) instability and low in vivo absorption."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.48
"It was found that the modification with adhesive materials improved PNS bioavailability in Fufang Danshen formula."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.48
"The pharmacokinetic parameters of bioactive components were significantly changed for better bioavailability and absorption, longer lasting time elimination, which were beneficial for enhancing therapeutic efficacy in the P-QSP group."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91

Dosage Studied

Ginsenoside Re is well tolerated up to a 375 mg/kg/day oral dosage level and non-toxic in both male and female rats. After oral administration, feces were collected at 12, 24, 36, 48, and 60 h.

ExcerptRelevanceReference
"A significant dose-response relationship was observed between increasing doses of pretreatment with AGBE and reduction in cisplatin-induced pica."( American ginseng berry extract and ginsenoside Re attenuate cisplatin-induced kaolin intake in rats.
Aung, H; Mehendale, S; Wang, A; Wang, CZ; Xie, JT; Yin, JJ; Yuan, CS, 2005
)
0.61
"Ginsenoside Re is well tolerated up to a 375 mg/kg/day oral dosage level and non-toxic in both male and female rats."( Chronic toxicity of ginsenoside Re on Sprague-Dawley rats.
Li, P; Liu, J; Lu, D; Zhao, W, 2012
)
2.15
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
nephroprotective agentAny protective agent that is able to prevent damage to the kidney.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
12beta-hydroxy steroid
3beta-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the beta-position.
beta-D-glucosideAny D-glucoside in which the anomeric centre has beta-configuration.
ginsenosideTriterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.
tetracyclic triterpenoidAny triterpenoid consisting of a tetracyclic skeleton.
disaccharide derivativeA carbohydrate derivative that is formally obtained from a disaccharide.
3beta-hydroxy-4,4-dimethylsteroidAny 3beta-hydroxy steroid which is substituted by two methyl groups at position 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 1Homo sapiens (human)IC50 (µMol)250.00000.02101.862610.0000AID480992
DNA topoisomerase 2-alphaHomo sapiens (human)IC50 (µMol)250.00000.48004.35649.9400AID480993
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)250.00000.00030.71237.0700AID480992
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
DNA topological changeDNA topoisomerase 1Homo sapiens (human)
chromatin remodelingDNA topoisomerase 1Homo sapiens (human)
circadian rhythmDNA topoisomerase 1Homo sapiens (human)
response to xenobiotic stimulusDNA topoisomerase 1Homo sapiens (human)
programmed cell deathDNA topoisomerase 1Homo sapiens (human)
phosphorylationDNA topoisomerase 1Homo sapiens (human)
peptidyl-serine phosphorylationDNA topoisomerase 1Homo sapiens (human)
circadian regulation of gene expressionDNA topoisomerase 1Homo sapiens (human)
embryonic cleavageDNA topoisomerase 1Homo sapiens (human)
chromosome segregationDNA topoisomerase 1Homo sapiens (human)
DNA replicationDNA topoisomerase 1Homo sapiens (human)
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 1Homo sapiens (human)
chromatin bindingDNA topoisomerase 1Homo sapiens (human)
double-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
single-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
RNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA topoisomerase type I (single strand cut, ATP-independent) activityDNA topoisomerase 1Homo sapiens (human)
protein serine/threonine kinase activityDNA topoisomerase 1Homo sapiens (human)
protein bindingDNA topoisomerase 1Homo sapiens (human)
ATP bindingDNA topoisomerase 1Homo sapiens (human)
DNA binding, bendingDNA topoisomerase 1Homo sapiens (human)
protein domain specific bindingDNA topoisomerase 1Homo sapiens (human)
supercoiled DNA bindingDNA topoisomerase 1Homo sapiens (human)
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nuclear chromosomeDNA topoisomerase 1Homo sapiens (human)
P-bodyDNA topoisomerase 1Homo sapiens (human)
fibrillar centerDNA topoisomerase 1Homo sapiens (human)
male germ cell nucleusDNA topoisomerase 1Homo sapiens (human)
nucleusDNA topoisomerase 1Homo sapiens (human)
nucleoplasmDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
perikaryonDNA topoisomerase 1Homo sapiens (human)
protein-DNA complexDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID359683Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID480993Inhibition of human DNA topoisomerase 2-mediated relaxation of supercoiled DNA by gel electrophoresis2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID359489Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359682Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID334335Induction of morphological transformation of rat ASK cells into astrocytes at 100 ug/ml after 1 hr by light microscopy
AID359495Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID480992Inhibition of human DNA topoisomerase 1-mediated relaxation of supercoiled DNA by gel electrophoresis2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID337110Hepatoprotective activity against D-galactosamine/LPS-induced liver injury in ddY mouse assessed as inhibition of serum aspartate transaminase level at 100 mg/kg, ip administered 1 hr before D-galactosamine/LPS challenge by Reitman-Frankel method2003Journal of natural products, Jul, Volume: 66, Issue:7
Structures of new dammarane-type Triterpene Saponins from the flower buds of Panax notoginseng and hepatoprotective effects of principal Ginseng Saponins.
AID359488Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID480999Cytotoxicity against human HL60 cells at 25 uM after 48 hrs by WST8 assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID359487Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID397814Induction of neurite outgrowth in human SK-N-SH cells at 100 uM after 5 days relative to control2002Journal of natural products, Sep, Volume: 65, Issue:9
Dammarane-type Saponins from Panax japonicus and their neurite outgrowth activity in SK-N-SH cells.
AID359484Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359494Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID359493Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID397122Inhibition of HIV1 RT
AID480997Cytotoxicity against human PC3 cells at 25 uM after 48 hrs by WST8 assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID481001Cytotoxicity against human PANC1 cells at 25 uM after 48 hrs by WST8 assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID359490Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID480995Cytotoxicity against human A549 cells at 25 uM after 48 hrs by WST8 assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID337107Hepatoprotective activity against D-galactosamine/LPS-induced liver injury in ddY mouse assessed as inhibition of serum alanine transaminase level at 100 mg/kg, ip administered 1 hr before D-galactosamine/LPS challenge by Reitman-Frankel method2003Journal of natural products, Jul, Volume: 66, Issue:7
Structures of new dammarane-type Triterpene Saponins from the flower buds of Panax notoginseng and hepatoprotective effects of principal Ginseng Saponins.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (194)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.52)18.7374
1990's4 (2.06)18.2507
2000's63 (32.47)29.6817
2010's102 (52.58)24.3611
2020's24 (12.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.79 (24.57)
Research Supply Index5.30 (2.92)
Research Growth Index5.90 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.02%)5.53%
Reviews3 (1.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other192 (97.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]